Bette Kennedy

Sublingual fentanyl tablets were generally well tolerated in patients with cancer-related breakthrough pain aged 65 years and older in conjunction with around-the-clock opioid treatment, investigators reported during the American Pain Society’s 30th Annual Scientific Meeting.

Methylnaltrexone bromide, a selective peripherally acting mu-opioid receptor antagonist, is effective for the long-term treatment of opioid-induced constipation resulting from chronic opioid therapy in chronic non-cancer pain, as demonstrated by study data presented at the American Pain Society’s 30th Annual Scientific Meeting.

At the American Pain Society’s 30th Annual Scientific Meeting, study data presented demonstrated that low-dose intrathecal morphine improves both Numeric Pain Rating Scale (NPS) scores and Multidimensional Pain Inventory (MPI) scores in patients with chronic non-cancer pain.

Fentanyl sublingual spray was significantly more effective at relieving breakthrough cancer pain at 30 minutes compared with placebo. That’s the conclusion of a randomized, double-blind, placebo-controlled, Phase 3 study that was presented during the American Pain Society’s 30th Annual Scientific Meeting.

Data presented at the American Pain Society’s 30th Annual Scientific Meeting demonstrated that NGX-4010, a capsaicin 8% patch significantly reduces pain in older patients with postherpetic neuralgia (PHN), a debilitating condition characterized by persistent pain following the healing of a herpes zoster rash.

A subgroup analysis presented at the American Pain Society’s 30th Annual Scientific Meeting demonstrated that fentanyl buccal soluble film is effective in the management of breakthrough neuropathic pain in cancer patients.

The effect of a fixed-dose combination of naproxen and esomeprazole on cyclooxygenase-1 (COX-1) inhibition by low-dose aspirin was found to be noninferior to low-dose aspirin alone in healthy subjects, according to the results of a Phase 1 study presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Use of bivalirudin after initial management with thrombolytics appears to be as safe as unfractionated heparin for primary percutaneous coronary intervention, according to the results of a retrospective study presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

A study presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session, revealed that administering a combination of aldosterone and angiotensin blockade for 4 months improves endothelial function compared with angiotensin blockade alone in women with signs and symptoms of ischemia and endothelial dysfunction.